Ipca Laboratories gains on entering into Technology Transfer Agreement with Omexa Formulary
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Ipca Laboratories is currently trading at Rs. 1208.25, up by 7.15 points or 0.60% from its previous closing of Rs. 1201.10 on the BSE.
The scrip opened at Rs. 1209.05 and has touched a high and low of Rs. 1220.35 and Rs. 1194.65 respectively. So far 12033 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1264.00 on 08-Feb-2024 and a 52 week low of Rs. 670.00 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1220.35 and Rs. 1142.60 respectively. The current market cap of the company is Rs. 30605.61 crore.
The promoters holding in the company stood at 46.29%, while Institutions and Non-Institutions held 44.79% and 8.92% respectively.
Ipca Laboratories has entered into a Technology Transfer Agreement with Omexa Formulary for a biosimilar clone, process development and knowledge transfer for the global market. Under this Agreement, Ipca will grant to Omexa a non-exclusive right to research, develop, manufacture and market a anti-cancer biosimilar for global market.
This Agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.
